HUTCHMED (HCM) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free HCM Stock Alerts GBX 320 -4.00 (-1.23%) (As of 06:57 AM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 5:22 AM | americanbankingnews.comHUTCHMED (LON:HCM) Shares Pass Above Two Hundred Day Moving Average of $271.21May 15, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)May 8, 2024 | markets.businessinsider.comHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeApril 24, 2024 | finance.yahoo.comHUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five yearsApril 21, 2024 | morningstar.comHUTCHMED (China) Ltd ADRMarch 28, 2024 | lse.co.ukLONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offerMarch 15, 2024 | finance.yahoo.comHCM Mar 2024 30.000 callFebruary 28, 2024 | markets.businessinsider.comHUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth PotentialFebruary 28, 2024 | finanznachrichten.deHUTCHMED (China) Limited: HUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesFebruary 28, 2024 | msn.comHutchison China MediTech reports FY resultsFebruary 28, 2024 | markets.businessinsider.comHUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesFebruary 28, 2024 | markets.businessinsider.comHUTCHMED Turns To Profit In FY23, Revenue Surges; Stock Up In Pre-marketFebruary 20, 2024 | au.finance.yahoo.comHUTCHMED (China) Ltd (H7T2.BE)February 20, 2024 | finance.yahoo.comHUTCHMED (China) Limited's (LON:HCM) biggest owners are private equity firms who got richer after stock soared 4.3% last weekFebruary 19, 2024 | msn.comWall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?February 7, 2024 | markets.businessinsider.comMaintaining Hold on HUTCHMED: Mixed FRUTIGA Results and Fair Valuation Limit UpsideFebruary 2, 2024 | markets.businessinsider.comHUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic PartnershipFebruary 2, 2024 | finance.yahoo.comHUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic PartnershipFebruary 1, 2024 | finance.yahoo.comHUTCHMED to Announce 2023 Final ResultsJanuary 30, 2024 | finanznachrichten.deHUTCHMED (China) Limited: HUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal CancerJanuary 30, 2024 | markets.businessinsider.comHUTCHMED Announces Marketing Approval For ELUNATE By Pharmacy And Poisons Board Of Hong KongJanuary 18, 2024 | msn.comAfter Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)November 30, 2023 | finance.yahoo.comHUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology CongressesNovember 30, 2023 | finance.yahoo.comHUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology CongressesNovember 27, 2023 | msn.comHUTCHMED (China) Limited - ADR (HCM) Price Target Increased by 5.11% to 26.63November 25, 2023 | benzinga.comHUTCHMED (China) Stock (NASDAQ:HCM), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | markets.businessinsider.comHUTCHMED’s Global Expansion and New Product Launches Bolster Buy Rating: An Analysis of Growth Prospects and Market PotentialNovember 10, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: HUTCHMED (HCM), Bayer (OtherBAYRY) and Compass Therapeutics (CMPX)November 6, 2023 | morningstar.comHUTCHMED (China) Ltd HCMOctober 16, 2023 | benzinga.comHUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023October 16, 2023 | finance.yahoo.comHUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023September 29, 2023 | stockhouse.comHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in JapanSeptember 25, 2023 | finance.yahoo.comIs HUTCHMED (China) Ltd (HCM) Set to Underperform? Analyzing the Factors Limiting GrowthSeptember 13, 2023 | finance.yahoo.comPrivate equity firms account for 44% of HUTCHMED (China) Limited's (LON:HCM) ownership, while institutions account for 28%September 11, 2023 | benzinga.comHUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in ChinaSeptember 11, 2023 | finance.yahoo.comHUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in ChinaSeptember 11, 2023 | finance.yahoo.comDecoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key MetricsAugust 29, 2023 | finanznachrichten.deHUTCHMED (China) Limited: HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric CancerAugust 28, 2023 | finance.yahoo.comHUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric CancerAugust 22, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for HUTCHMED (HCM)August 21, 2023 | markets.businessinsider.comGoldman Sachs Remains a Hold on HUTCHMED (HCM)August 11, 2023 | msn.comHutchmed: Attractive Chinese R&D GiantAugust 3, 2023 | finance.yahoo.comHUTCHMED (China) First Half 2023 Earnings: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)July 19, 2023 | finance.yahoo.comWall Street Analysts Think HUTCHMED (HCM) Could Surge 141.13%: Read This Before Placing a BetJuly 9, 2023 | finance.yahoo.comHUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in ChinaJune 26, 2023 | finance.yahoo.comHUTCHMED to Announce 2023 Half-Year Financial ResultsJune 16, 2023 | finanznachrichten.deHUTCHMED (China) Limited: HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The LancetJune 1, 2023 | finance.yahoo.comHUTCHMED (China) (LON:HCM investor five-year losses grow to 53% as the stock sheds UK£125m this past weekMay 25, 2023 | finance.yahoo.comHUTCHMED Highlights Presentations at the 2023 ASCO Annual MeetingMay 25, 2023 | finance.yahoo.comTakeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address 4 Cryptos BETTER than Bitcoin (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin Click For My #1 FREE Crypto for 2024 HCM Media Mentions By Week HCM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HCM News Sentiment▼0.170.42▲Average Medical News Sentiment HCM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HCM Articles This Week▼20▲HCM Articles Average Week Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INDV News Today HIK News Today DPH News Today EMIS News Today GNS News Today SPI News Today ONT News Today CRW News Today CTEC News Today SN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:HCM) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
